Business News • PR NewsWire • Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Shionogi to conduct clinical trials, subsequent registration, and commercialization of olorofim for invasive aspergillosis (IA) in Europe and Asia F2G to receive upfront payment of $100m and share development costs F2G will also be eligible for additional regulatory and commercial...

View More : https://www.prnewswire.com:443/news-releases/shionogi--co-ltd-and-f2g-ltd-enter-strategic-collaboration-to-develop-and-c...

Releted News by prnewswire

Fast Buds launches the most potent autoflowering seeds for 2022

Diadem Announces Publication of Clinical Study Confirming Its AlzoSure® Predict Blood Test Can Accurately Predict Progression to Alzheimer's Disease Six Years Before Diagnosis

MoEngage Launches a New WhatsApp Business Integration for Enterprises

Worldwide Express Celebrates 30th Anniversary with Primary Sponsorship Debut in NASCAR Cup Series